Shin Nippon Biomedical Laboratories, Ltd. (FRA:YB3)

Revenue by Segment

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017	Mar 31, 2016
US Property Management Business	45.98M	-	-	-	-
Translational Research Business	54.16M	13.23M	16.48M	12.86M	12.24M
Translational Research Business Growth	309.47%	-19.74%	28.13%	5.06%	918.47%
Other	1.79B	1.41B	1.44B	968.97M	503.87M
Other Growth	27.21%	-2.09%	48.34%	92.31%	233.73%
Medipolis Business	564.93M	569.08M	683.66M	563.50M	552.18M
Medipolis Business Growth	-0.73%	-16.76%	21.32%	2.05%	-44.90%
CRO Business	31.60B	25.91B	24.00B	17.05B	14.51B
CRO Business Growth	21.94%	7.96%	40.78%	17.50%	-
Unallocated Adjustments	-1.64B	-1.45B	-1.05B	-844.70M	-466.60M
Total	32.41B	26.45B	25.09B	17.75B	15.11B
Total Growth	22.55%	5.42%	41.37%	17.46%	3.77%

Revenue by Geography

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017	Mar 31, 2016
United States of America	6.37B	4.48B	3.84B	-	1.64B
United States of America Growth	42.18%	16.62%	-	-	31.79%
Others	498.21M	393.21M	2.73B	-	455.65M
Others Growth	26.70%	-85.61%	-	-	-57.38%
Japan	21.52B	17.81B	18.52B	-	13.01B
Japan Growth	20.84%	-3.80%	-	-	6.26%
Korea	4.02B	3.76B	-	-	-
Korea Growth	6.79%	-	-	-	-
Total	32.41B	26.45B	25.09B	-	15.11B
Total Growth	22.55%	5.42%	-	-	3.77%

Source: S&P Global Market Intelligence.